




Summary of capital reduction pursuant to Article 32 of the Danish Capital Markets Act

With reference to Novozymes' Company announcement No. 13/2018, a reduction of DKK 16,000,000 in the Company's B common stock via the cancellation of 8,000,000 B shares of the Company's treasury stock was carried out on April 12, 2018, following the adoption of this proposal at the Company's annual shareholders' meeting on March 13, 2018.

Following the above, and pursuant to Article 32 of the Danish Capital Markets Act No. 12 of January 8, 2018, the Company announces that its total capital stock as of today consists of nominally DKK 594,000,000, divided into 297,000,000 shares, corresponding to 53,743,600 A shares and 243,256,400 B shares with a nominal value of DKK 2 each and a total of 1,561,384,800 voting rights.

April 30, 2018
Company announcement No. 20

Contact information
novozymesIR@novozymes.com

Tobias Cornelius Björklund
+45 3077 8682
tobb@novozymes.com

Klaus Sindahl
+45 5363 0134
ksdh@novozymes.com

About Novozymes

Novozyymes is the world leader in biological solutions. Together with customers, partners and the global community, we improve industrial performance while preserving the planet's resources and helping build better lives. As the world's largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow. www.novozymes.com

Novozyymes A/S CVR number: 10 00 71 27 LEI: 529900T6WNZXD2R3JW38

Novozyymes A/S
Krogshøjvej 36
2880 Bagsvaerd
Denmark

Phone: +45 4446 0000

Rethink Tomorrow

novozymes 